<DOC>
	<DOCNO>NCT00885742</DOCNO>
	<brief_summary>Congenital deficiency factor XIII ( FXIII ) extremely rare inherit disorder associate potentially life-threatening bleeding . Factor XIII Concentrate give patient whose blood lack factor XIII . Factor XIII Concentrate work assist blood usual clotting process , thereby prevent bleed . In study , patient treat FXIII Concentrate ( Human ) follow closely determine receive dose best minimize chance bruise bleeding .</brief_summary>
	<brief_title>A Study Factor XIII Concentrate Subjects With Congenital Factor XIII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Factor XIII Deficiency</mesh_term>
	<criteria>Written inform consent/assent study participation obtain undergoing studyspecific procedure Documented congenital FXIII deficiency require prophylactic treatment FXIII contain product . Males females age congenital FXIII deficiency Received full hepatitis B vaccination and/or hepatitis B surface antibody positive Diagnosis acquire FXIII deficiency Administration FXIIIcontaining product , include blood transfusion blood product within 4 week prior plan Day 0 Any known congenital acquire coagulation disorder congenital FXIII deficiency Known suspect antibody towards FXIII Use investigational medicinal product within 4 week prior Baseline Visit ( Day 0 ) Known Positivity human immunodeficiency virus ( HIV ) positive result HIV Screening Visit study FXIII study 2002 ( NCT00883090 ) . Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) concentration &gt; 2.5 time upper limit normal Screening Visit study Day 56 Visit Factor XIII Study BI71023_2002 ( NCT00883090 ) Fibrinogen level le 85 % low limit normal Screening Visit study Factor XIII Study BI71023_2002 ( NCT00883090 ) Active bleed ≥ Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 and/or ≥ moderate Screening Baseline Visits Pregnant breastfeed Intention become pregnant course study Female subject childbearing potential use , willing use , medically reliable method contraception entire duration study Suspected inability ( e.g. , language problem ) unwillingness comply study procedure history noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hereditary Factor XIII deficiency</keyword>
	<keyword>Factor XIII</keyword>
</DOC>